Impact of Probiotics on Symptom Control in Irritable Bowel Syndrome
DOI:
https://doi.org/10.54112/bcsrj.v6i8.1963Keywords:
Irritable Bowel Syndrome, Probiotics, Gut Microbiota, Symptom Control, Quality of LifeAbstract
Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits, with a significant impact on patients' quality of life. Intervention. Objective: To evaluate the impact of probiotic supplementation on symptom control and quality of life in patients with IBS. Methods: This observational study was conducted at Naseer Ullah Babar Hospital, Kohat Road, Peshawar, from January 2025 to June 2025. A total of 160 IBS patients fulfilling Rome IV criteria were randomized to receive either a probiotic formulation (containing Lactobacillus and Bifidobacterium species) or a placebo for 12 weeks, in addition to standard lifestyle advice. Results: At week 12, the probiotic group showed a greater reduction in IBS-SSS compared with placebo (122.4 ± 65.2 vs. 82.1 ± 61.8, p = 0.003). A clinical response (defined as a≥50-point reduction in IBS-SSS) was achieved in 68.7% of patients treated with probiotics, compared to 46.2% in the placebo group (p = 0.004). Significant improvements were observed in abdominal pain (48.6% vs. 31.4%, p = 0.01), bloating (44.2% vs. 25.7%, p = 0.008), stool normalization (52.5% vs. 33.7%, p = 0.02), and quality of life (mean improvement 34.6 ± 12.4 vs. 21.8 ± 11.7, p < 0.001). Both interventions were well tolerated, with no serious adverse events. Conclusion: Probiotic supplementation is effective in reducing IBS symptom severity, improving bowel-related outcomes, and enhancing quality of life, with an excellent safety profile. These findings support the role of probiotics as a safe and beneficial adjunct in the management of IBS.
Downloads
References
Satish Kumar L, Pugalenthi LS, Ahmad M, Reddy S, Barkhane Z, Elmadi J. Probiotics in irritable bowel syndrome: a review of their therapeutic role. Cureus. 2022 Apr 18;14(4):e24240. https://doi.org/10.7759/cureus.24240
Abrar M, Iqbal T, Farooq MA, Aziz A, Sarwar K. Role of probiotics in irritable bowel syndrome (IBS). In: Farooqi SH, Aqib AI, Zafar MA, Akhtar T, Ghafoor N, editors. Complementary and Alternative Medicine: Prebiotics and Probiotics. Faisalabad (Pakistan): Unique Scientific Publishers; 2024. p. 340–350. https://doi.org/10.47278/book.CAM/2024.289
Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, Petrovic G, Zivkovic V. Irritable bowel syndrome—from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018;162(1):1–9. https://doi.org/10.5507/bp.2017.057
Di Rosa C, Altomare A, Terrigno V, Carbone F, Tack J, Cicala M, et al. Constipation-predominant irritable bowel syndrome (IBS-C): effects of different nutritional patterns on intestinal dysbiosis and symptoms. Nutrients. 2023;15(7):1647. https://doi.org/10.3390/nu15071647
Fikree A, Byrne P. Management of functional gastrointestinal disorders. Clin Med (Lond). 2021;21(1):44–52. https://doi.org/10.7861/clinmed.2020-0980
Gendi R, Jahan N. Pharmacological and non-pharmacological treatments of irritable bowel syndrome and their impact on the quality of life: a literature review. Cureus. 2020 Jul 9;12(7):e9324. https://doi.org/10.7759/cureus.9324
Grumet L, Tromp Y, Stiegelbauer V. The development of high-quality multispecies probiotic formulations: from bench to market. Nutrients. 2020;12(8):2453. https://doi.org/10.3390/nu12082453
Gulliver EL, Young RB, Chonwerawong M, D'Adamo GL, Thomason T, Widdop JT, et al. Review article: the future of microbiome-based therapeutics. Aliment Pharmacol Ther. 2022;56(2):192–208. https://doi.org/10.1111/apt.17049
Guo P, Zhang K, Ma X, He P. Clostridium species as probiotics: potentials and challenges. J Anim Sci Biotechnol. 2020;11:24. https://doi.org/10.1186/s40104-019-0402-1
Zhang WX, Shi LB, Zhou MS, Wu J, Shi HY. Efficacy of probiotics, prebiotics, and synbiotics in irritable bowel syndrome: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. J Med Microbiol. 2023;72(9):001758. https://doi.org/10.1099/jmm.0.001758
Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020 Nov 21;396(10263):1675–1688. https://doi.org/10.1016/S0140-6736(20)31548-8
Videlock EJ, Chang L. Latest insights on the pathogenesis of irritable bowel syndrome. Gastroenterol Clin North Am. 2021;50(3):505–522. https://doi.org/10.1016/j.gtc.2021.04.002
de Sire A, de Sire R, Curci C, Castiglione F, Wahli W. Role of dietary supplements and probiotics in modulating microbiota and bone health: the gut-bone axis. Cells. 2022;11(4):743. https://doi.org/10.3390/cells11040743
Depoorter L, Vandenplas Y. Probiotics in pediatrics: a review and practical guide. Nutrients. 2021;13(7):2176. https://doi.org/10.3390/nu13072176
Pimentel M, Lembo A. Microbiome and its role in irritable bowel syndrome. Dig Dis Sci. 2020;65(3):829–839. https://doi.org/10.1007/s10620-020-06109-5
Defaye M, Gervason S, Altier C, Berthon J-Y, Ardid D, Filaire E, et al. Microbiota: a novel regulator of pain. J Neural Transm (Vienna). 2020;127(4):445–465. https://doi.org/10.1007/s00702-019-02083-z
Tran C, Cock IE, Chen X, Feng Y. Antimicrobial Bacillus: metabolites and their mode of action. Antibiotics (Basel). 2022;11(1):88. https://doi.org/10.3390/antibiotics11010088
Tremblay A, Xu X, Colee J, Tompkins TA. Efficacy of a multi-strain probiotic formulation in pediatric populations: a comprehensive review of clinical studies. Nutrients. 2021;13(6):1908. https://doi.org/10.3390/nu13061908
Zheng Y, Zhang Z, Tang P, Wu Y, Zhang A, Li D, et al. Probiotics fortify intestinal barrier function: a systematic review and meta-analysis of randomized trials. Front Immunol. 2023;14:1143548. https://doi.org/10.3389/fimmu.2023.1143548
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mariana Amer, Shandana Altaf, Syed Mehtab Ullah Kakakhel
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
